Sir, Training in trabeculectomy
I read with interest the clinical study of Welch et al.
1
The study highlights the fact that with a decrease in glaucoma surgery trainees have less opportunity for gaining experience in trabeculectomy.
I have worked in West Africa for over 20 years and am the medical director of a 62-bed eye hospital in the north of Benin. In 2010 over 3500 eye surgeries were performed, of which 395 were trabeculectomies. Open-angle glaucoma is common and is a major cause of blindness. The potent anti-glaucoma medications used in the United Kingdom are too expensive for our poor patients or are unavailable. In any case, many of the glaucoma patients we see have intraocular pressures of 50 or 60 mm Hg and would not respond sufficiently to eye drops however potent. Hence, surgery is the only practical solution.
One possibility for glaucoma surgery training would be for a partnership between hospitals in the United Kingdom and eye hospitals in West Africa, 'the glaucoma capital of the world'. We have the patients. UK consultants and their trainees would be welcome here for short periods.
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The author declares no conflict of interest. 3-5 We conducted a pilot study to evaluate the efficacy of intravitreal bevacizumab (IVB) as a preoperative adjunct for primary TMMC to treat NVG in previously vitrectomised eyes.
A total of 15 eyes of 15 consecutive patients (10 men, 5 women) who had undergone a previous vitrectomy received IVB (1 mg) followed by planned TMMC. All patients were followed for more than 1 year postoperatively. The mean patient age was 58.3 ± 11.3 years (31-71 years). NVG was secondary to proliferative diabetic retinopathy in 11 eyes (73%), ocular ischaemic syndrome in 3 eyes (20%), and central retinal vein occlusion in 1 eye (7%). A total of 11 eyes had one, 2 eyes had two, and 2 eyes had three previous vitrectomies. The interval between IVB and TMMC was 10.0±6.4 days (1-22 days). All patient data are shown in Table 1 .
The mean intraocular pressure (IOP) reduced significantly from 41.3 ± 11.9 mm Hg (25-62 mm Hg) at baseline to 13.6±7.0 mm Hg (4-32 mm Hg, Po0.001, one-way ANOVA followed by Tukey's test) at 1 month, 13.9 ± 4.5 mm Hg (6-18 mm Hg, Po0.001) at 3 months, 15.3 ± 5.1 mm Hg (8-23 mm Hg, Po0.001) at 6 months, and 15.4±5.2 mm Hg (4-25 mm Hg, Po0.001) at 1 year postoperatively. The success rates defined as IOP below 21 mm Hg without loss of light perception and additional anti-glaucoma surgeries were 87% after 1 and 3 months of follow-up, 80% after 6 months, and 73% after 1 year (Figure 1 ). Failure (four eyes, 27%) was attributed to the additional glaucoma surgery in three eyes and an IOP over 21 mm Hg in one eye.
Previous studies have reported that the 1-year success rate of TMMC without bevacizumab for NVG in previously vitrectomised eyes was about 50%, which is lower than that of the current study.
1,2 Preoperative adjunctive use of bevacizumab before trabeculectomy might improve the surgical success rate of NVG in previously vitrectomised eyes. Figure 1 Kaplan-Meier survival curve analysis of surgical outcomes in 15 eyes treated with adjunctive intravitreal bevacizumab followed by trabeculectomy with mitomycin C. Cumulative survival (success) is defined as an intraocular pressure of 21 mm Hg or lower without additional anti-glaucoma surgery and loss of light perception vision. The overall success was 73% at 1 year.
